Category: Markets
Published: 2026-06-28T19:58:00.000Z
DexCom, Inc. (DXCM) announced FDA clearance for expanded use of its Stelo Glucose Biosensor, now including children aged 2 and older who do not use insulin. This move aims to broaden access to glucose biosensing and preventive care through a redesigned Stelo app, set to roll out in the U.S. in July and internationally starting later this year. The company emphasizes the growing prevalence of Type 2 diabetes in young people and the new ability for non-insulin users to track blood sugar without a prescription.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.